| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2035273 | Cell | 2015 | 13 Pages |
•Tumor and normal organoids were derived from colorectal carcinoma patients•Tumor organoids recapitulate somatic copy number and mutation spectra found in CRC•Organoids are amenable to high-throughput drug screening•Patient-derived organoids allow personalized therapy design
SummaryIn Rspondin-based 3D cultures, Lgr5 stem cells from multiple organs form ever-expanding epithelial organoids that retain their tissue identity. We report the establishment of tumor organoid cultures from 20 consecutive colorectal carcinoma (CRC) patients. For most, organoids were also generated from adjacent normal tissue. Organoids closely recapitulate several properties of the original tumor. The spectrum of genetic changes within the “living biobank” agrees well with previous large-scale mutational analyses of CRC. Gene expression analysis indicates that the major CRC molecular subtypes are represented. Tumor organoids are amenable to high-throughput drug screens allowing detection of gene-drug associations. As an example, a single organoid culture was exquisitely sensitive to Wnt secretion (porcupine) inhibitors and carried a mutation in the negative Wnt feedback regulator RNF43, rather than in APC. Organoid technology may fill the gap between cancer genetics and patient trials, complement cell-line- and xenograft-based drug studies, and allow personalized therapy design.PaperClip To listen to this audio, enable JavaScript on your browser. However, you can download and play the audio by clicking on the icon belowHelp with MP3 filesOptionsDownload audio (3316 K)
Graphical AbstractFigure optionsDownload full-size imageDownload high-quality image (184 K)Download as PowerPoint slide
